Press

  • aside

    Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in…

    by
  • aside

    Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal…

    by
  • aside

    From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study…

    by
  • aside

    Isofols appoints Sven Erickson as Chief Commercial Officer

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of  Sven Erickson as Chief…

    by
  • aside

    Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera,…

    by
  • aside

    Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking…

    by